Insider selling
Traded Nov 12, 2025 · filed 1 day laterNot reported under a pre-arranged trading plan
A major shareholder of Eli Lilly sold $830K of Eli Lilly shares. The filing does not indicate a pre-arranged trading plan.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Oct 10, 2025 · Filed Oct 14, 2025
A major shareholder of Eli Lilly sold $2.75M of Eli Lilly shares. The filing does not indicate a pre-arranged trading plan.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$2,754,147
Shares × reported transaction price
64 days after results of Aug 7, 2025, 20 days before results of Oct 30, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Closed at $833.49 on Oct 10, 2025, 33% above its 52-week low and 11% below its high, after a 14% rise over the previous 30 trading days
52-week range $625.65 (Aug 8, 2025) to $932.06 (Oct 11, 2024), 68% of the way up, from 250 adjusted closes. 30 trading days earlier: $731.96 on Aug 28, 2025. Describes the past only, not a forecast
None found in footnotes
Only flagged when a footnote says so; never inferred
FDA approved Inluriyo on Sep 25, 2025, 15 days before this trade.
New drug application approved. Active ingredient: Imlunestrant Tosylate. From openFDA. Dates only; no link between the two is implied
| After | Stock | S&P 500 | Difference |
|---|---|---|---|
| 7 days | −1.7% | +0.4% | −2.1% |
| 30 days | +24.0% | +1.0% | +23.0% |
| 90 days | +30.3% | +4.3% | +26.0% |
| 180 days | +12.5% | +3.1% | +9.3% |
| 365 days | +51.4% | +16.0% | +35.4% |
Past results only. Not a forecast.
Insider selling
Traded Nov 12, 2025 · filed 1 day laterNot reported under a pre-arranged trading plan
A major shareholder of Eli Lilly sold $830K of Eli Lilly shares. The filing does not indicate a pre-arranged trading plan.
Insider selling
6 days before an 8-KTraded Nov 12, 2025 · filed 1 day laterNot reported under a pre-arranged trading plan
A major shareholder of Eli Lilly sold $24M of Eli Lilly shares. The filing does not indicate a pre-arranged trading plan.
Insider selling
6 days before an 8-KTraded Nov 12, 2025 · filed 1 day laterNot reported under a pre-arranged trading plan
A major shareholder of Eli Lilly sold $8.98M of Eli Lilly shares. The filing does not indicate a pre-arranged trading plan.
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.